Percutaneous transluminal septal myocardial ablation

Current Cardiology Reports

Volumn 2, Issue 2, 2000, Pages 160-165

  Rubin, David N ^a   Tuzcu, E Murat ^a   Lever, Harry M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL HEART PACEMAKER; CATHETER ABLATION; HEART LEFT VENTRICLE FUNCTION; HEART OUTFLOW TRACT OBSTRUCTION; HEART STROKE VOLUME; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW;

CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; HUMANS; PACEMAKER, ARTIFICIAL; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 0034149625     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0014-5     Document Type: Article

References (48)

1. Sherrid MV, Chu CK, Delia E, et al. : An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J Am Coll of Cardiol 1993, 22:816-825.
2. Pollick C, Rakowski H, Wigle ED: Muscular subaortic stenosis: the quantitative relationship between systolic anterior motion and the pressure gradient. Circulation 1984, 69:43-49.
3. Wigle ED, Henderson M, Rakowski H, et al. : Muscular (hypertrophic) subaortic stenosis (hypertrophic obstructive cardiomyopathy): the evidence for true obstruction to left ventricular outflow. Postgrad Med J 1986, 62:531-536.
4. Maron BJ, Gardin JM, Flack JM, et al. : Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995, 92:785-789.
5. Backes RJ, Gersh BJ: Cardiomyopathies in the elderly. Cardiovascular Clinics 1992, 22:105-125.
6. Cannan CR, Reeder GS, Bailey KR, et al. : Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation 1995, 92:2488-2495.
7. Cecchi F, Olivotto I, Montereggi A, et al. : Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995, 26:1529-1536.
8. Dimitrow PP, Dubiel JS: Effects on left ventricular function of pindolol added to verapamil in hypertrophic cardiomyopathy. Am J of Cardiol 1993, 71:313-316.
9. Sherrid M, Delia E, Dwyer E: Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1988, 62:1085-1088.
10. Gilligan DM, Chan WL, Joshi J, et al. : A double blind, placebocontrolled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol 1993, 21:1672-1679.
11. Hasin Y, Lewis BS, Lewis N, et al. : Long-term effect of verapamil in hypertrophic cardiomyopathy. Int J Cardiol 1982, 1:243-251.
12. Hanrath P, Schluter M, Sonntag F, et al. : Influence of verapamil therapy on left ventricular performance at rest and during exercise in hypertrophic cardiomyopathy. Am J Cardiol 1983, 52:544-548.
13. Fananapazir L, Cannon R, Tripodi D, et al. : Impact of dualchamber pacing in patients with obstructive hypertophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic-blocker therapy. Circulation 1992, 85:2149-2161.
14. Fananapazir L, Epstein ND, Curiel RV, et al. : Long-term results of dual chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence of progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertophy. Circulation 1994, 90:2731-2742.
15. Kappenberger L, Linde C, Daubert C, et al. : Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. IC Study Group. Eur Heart J 1997, 18:1249-1256.
16. Nishimura RA, Trusty JM, Hayes DL, et al. : Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, doubleblind, crossover trial. J Am Coll Cardiol 1997, 29:435-441.
17. Betocchi S, Losi MA, Piscione F, et al. : Effects of dual-chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstruction and on diastolic function. Am J Cardiol 1996, 77:498-502.
18. Linde C, Gadler F, Kappenberger L, et al. : Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. Am J Cardiol 1999, 83:903-907.
19. Beahrs MM, Tajik AJ, Seward JB et al. : Hypertrophic obstructive cardiomyopathy: ten to 21 year follow-up after partial septal myectomy. Am J of Cardiol 1983, 51:1160-1166.
20. Bircks W: Surgical treatment of hypertrophic cardiomyopathy (Dusseldorf experience). Postgrad Med J 1986, 62:571-574.
21. Cohn LH, Trehan H, Collins JJ, Jr: Long-term follow up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1992, 70:657-660.
22. Heric B, Lytle BW, Miller DP, et al. : Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg 1995, 110:195-206.
23. Koch JP, Maron BJ, Epstein SE, et al. : Results of operation for obstructive hypertrophic cardiomyopathy in the elderly. Septal myotomy and myectomy in 20 patients 65 years of age or older. Am J Cardiol 1980, 46:963-966.
24. Maron BJ, Epstein SE, Morrow AG: Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy. Eur Heart J 1983, 4(Suppl F):175-185.
25. Mohr R, Schaff HV, Danielson GK, et al. : The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy. Experience over 15 years. J Thorac Cardio Surg 1989, 97:666-674.
26. Morrow AG, Reitz BA, Epstein SE, et al. : Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975, 52:88-102.
27. Morrow AG, Koch JP, Maron BJ, et al. : Left ventricular myotomy and myectomy in patients with obstructive hypertrophic cardiomyopathy and previous cardiac arrest. Am J Cardiol 1980, 46:313-316.
28. Williams WG, Wigle ED, Rakowski H, et al. : Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation 1987, 76:V104-V108.
29. ten Berg JM, Suttorp MJ, Knaepen PJ, et al. : Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow up after Morrow septal myectomy. Circulation 1994, 90:1781-1785.
30. Robbins RC, Stinson EB: Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovas Surg 1996, 111:586-594.
31. Sigwart U: Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995, 346:211-214.
32. Rubin DN, Tuzcu EM, Drinko JK, et al. : Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy eliminates resting obstruction, not provokable obstruction while improving quality of life [abstract]. J Am Coll Cardiol 1999, 33(2, Suppl A):502A.
33. Geitzen FH, Horst JK, Leuner CJ, et al. : Acute and long-term results after transcoronary ablation of septum hypertrophy by selective septal branch injection of ethanol. A catheter interventional treatment for hypertrophic obstructive cardiomyopathy [abstract]. Circulation 1998, 98:I-86.
34. Kim JJ, Lee CW, Park SW, et al. : Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol 1999, 83:1220-1223.
35. Lakkis NM, Nagueh SF, Killip DM, et al. : Non-surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one year follow-up [abstract]. J Am Coll Cardiol 1999, 33(2, Suppl A):502A.
36. Faber L, Seggewiss H, Ziemssen P, et al. : Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy (HOCM): intra-procedural myocardial contrast echocardiography as a routine procedure. J Am Coll Cardiol 1999, 33(2, Suppl A):501A.
37. Kazmierczak J, Kornacewicz-Jach Z, Kisly M, et al. : Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Heart 1998, 80(3):257-62.
38. Knight C, Kurbaan AS, Seggewiss H, et al. : Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997, 95:2075-2081.
39. Seggewiss H, Gleichmann U, Faber L, et al. : Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow up in 25 patients. J Am Coll Cardiol 1998, 31:252-258.
40. Lakkis NM, Nagueh SF, Kleiman NS, et al. : Echocardiographyguided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998, 98:1750-1755.
41. Boekstegers P, Steinbigler P, Schwaiblmair M, et al. : Transcoronary ablation of septal hypertrophy (TASH) inducing smaller infarctions shows similar hemodynamic and clinical effects (medium term follow-up) but a low complication rate in patients with hypertrophic obstructive cardiomyopathy [abstract]. Circulation 1998, 98(17 Suppl):I-444.
42. Kim JJ, Lim HY, Lee HJ, et al. : Improved exercise capacity and exercise hemodynamics are sustainable up to one year after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy [abstract]. Circulation 1998, 98(17 Suppl):I-432.
43. Nagueh SF, Lakkis NM, Middleton KJ, et al. : Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999, 99:344-347.
44. Seggewiss H, Faber L, Gleichmann U, et al. : Remodeling after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy results in ongoing outflow tract gradient reduction [abstract]. J Am Coll Cardiol 1999, 33(2 Suppl A):490A.
45. Marwick TH, Stewart WJ, Lever HM, et al. : Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol 1992, 20:1066-1072.
46. Faber L, Seggewiss H, Gleichmann U: Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy results with respect to intramyocardial contrast echocardiography. Circulation 1998, 98:2415-2421.
47. Nagueh SF, Lakkis NM, He ZX, et al. : Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1998, 32:225-229.
48. Faber L, Seggewiss H, Ziemssen P, et al. : Regression of left ventricular free wall hypertrophy after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy is independent of coexistent systematic arterial hypertension [abstract. J Am Coll Cardiol 1999, 33(2, Suppl A):502A.